



Advances in Cancer and Virus-Host Cell Interactions

Guest Editors:

Dr. Mubashir Javed Mintoo

Department of Cell and
Molecular Pharmacology and
Experimental Therapeutics,
Medical University of South
Carolina, 171 Ashley Avenue,
Charleston, SC 29425, USA

Dr. Rakesh Sathish Nair

Department of Cell and
Molecular Pharmacology,
Medical University of South
Carolina, 171 Ashley Avenue,
Charleston, SC 29425, USA

Deadline for manuscript
submissions:

31 October 2024

Message from the Guest Editors

The aim of this Special Issue is to provide a comprehensive and updated overview of the current knowledge and challenges in the field of cancer and virus–host cell interactions.

We welcome contributions from researchers working on different types of viruses that are linked to human cancers, such as human papillomaviruses (HPVs), hepatitis viruses B and C (HBV and HCV), human gammaherpesviruses (HHV4/Epstein–Barr Virus (EBV) and HHV8/Kaposi's Sarcoma-Associated Herpesvirus (KSHV), Merkel cell polyomavirus (MCPyV), and human T-cell leukemia virus I (HTLV-1). We also encourage submissions that explore the interactions between viruses and other factors that influence cancer development, such as genetics, epigenetics, immunity, metabolism, microbiome, etc.

The scope of this Special Issue is to provide a platform for researchers to share their latest findings and insights on the complex interplay between cancer and virus–host cell interactions. We hope that this Special Issue will stimulate further research and collaboration in this important and rapidly evolving field of biomedicine.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)